Introduction
Human papillomavirus (HPV) infection is highly common among sexually active young adults, with an estimated prevalence between 20.0% and 46.0% 1 . HPV oncogenic types are the principal cause of cervical cancer, because they are capable of inducing cellular immortalization with transformation to the malignant phenotype and loss of tumor suppressor genes 1, 2 . In children, the virus can cause recurrent respiratory papillomatosis (RRP), a benign and rare disease almost always caused by one of two HPV types, HPV6 or HPV11. However, cervical cancer is an aggressive neoplasm that produces considerable morbidity 3, 4 .
The association between sexual activity and cervical cancer has been known. It is also well recognized that high-risk HPV is spread by sexual activity 1 . There is growing evidence that HPV infection is acquired through non-sexual routes, and that one potential route is motherto-child transmission in the perinatal period 5, 6, 7, 8 . Although epidemiological trials suggest the possibility of non-sexual transmission, there is evidence of vertical transmission, presumably occurring during passage of the fetus through an infected birth canal. The virus could also be transmitted by ascending infection, principally after premature rupture of membranes 5, 6, 7 . Elective cesarean delivery could benefit infants of HPV DNA-positive mothers by reducing the Cad. Saúde Pública, Rio de Janeiro, 21(4):1006-1015, jul-ago, 2005 neonatal contamination rate 8 . However, whether cesarean delivery could prevent transmission of the virus from HPV-positive mothers remains to be determined 8 .
In order to better understand the exact mode and risk of vertical transmission in asymptomatic pregnant women, as well as the relationship between HPV transmission and mode of delivery, we have proposed this systematic quantitative review.
Methods

Search strategy
We conducted a complete search of MEDLINE The following key words were used: HPV, pregnancy, newborn infants, vertical transmission, maternal-fetal transmission, perinatal infection, and perinatal transmission. Reference lists of all available primary studies were reviewed to identify additional relevant citations. There were no language restrictions. We attempted to contact the respective authors.
Selection criteria
This was a review of prospective cohort studies including pregnant women from all races and ages which examined transmission of HPV infection to newborns. HPV infection was investigated by polymerase chain reaction (PCR) in the maternal cervix between 20 and 40 weeks of gestation, and in the newborn infant's oral mucosa and/or genital area at delivery. Retrospective cohort studies, case-control studies, and case-series were excluded.
Three outcomes were measured: (1) HPV prevalence in pregnant women and newborns in each trial; (2) risk of mother-to-child HPV transmission defined as a positive HPV test (PCR); (3) risk of mother-to-child HPV transmission according to mode of delivery.
The reviewed studies were identified independently by four investigators (L. R. M., A. B. M. E., R. R. Z. and O. B. S.). All trials which appeared relevant on the basis of "title", "abstract", and "MeSH headings" were selected for full review by three independent reviewers. Articles were only rejected on initial screening if it could be determined from the title or abstract that the article was not a report of a prospective cohort study. Final inclusion and exclusion was made with reference to a checklist, which consisted of items based on the selection criteria.
Quality assessment
All articles meeting the eligibility criteria were assessed for their methodological quality. This assessment involved scrutinizing study designs and relevant features of population, test, and reference standards 9, 10 . Each trial's quality was assessed by two different methods. In the first method the results were summarized using the Ottawa-Newcastle system 10 , in particular the use of stars awarded for each criterion in three domains (cohort selection, cohort comparability, and outcome) ( Table 1 ). Studies were further assessed for methodological quality with reference to the Oxford Center for EvidenceBased Medicine Levels of Evidence Classification rubric 11 . Only studies with Oxford Evidence Levels 1 to 3 were considered classified as high-quality, while those with levels 4 and 5 were excluded. These features included the data collection and patient selection methods, definition of a positive HPV test (PCR) in pregnant women and newborns, and presence of verification bias 12, 13, 14, 15 .
Data extraction
English-language articles were assessed by 2 reviewers (L. R. M. and A. B. M. E.) and those published in other languages were evaluated independently by 2 different reviewers (R. R. Z. and O. B. S.) following translation (when necessary). Disagreements were resolved by consensus, and when this was not possible, by arbitration with a fifth reviewer (M. C. B.).
From the potentially relevant articles, four reviewers independently selected the studies (based on the full-text format) for inclusion in this review. Thus, three outcomes were considered: (1) HPV prevalence in pregnant women and newborns; (2) risk of mother-to-child HPV transmission; (3) risk of mother-to-child HPV transmission according to mode of delivery. HPV prevalence data were calculated separately for sources with positive and negative results. Transmission risk data were abstracted as 2x2 tables (newborns HPV-positive/negative versus mothers HPV-positive/negative). Similarly, a contingency table was produced for Table 1 Ottawa-Newcastle quality assessment scale cohort studies 10 . mother-to-child HPV transmission risk according to mode of delivery (newborns HPV-positive/cesarean versus newborns HPV-positive/ vaginal delivery).
Domains, cohort studies
Statistical aspects
To evaluate agreement between study eligibility and methodological quality assessment, the observed percentage agreement and κ coefficient for inter-rater reliability were calculated 12 . HPV prevalence rates in pregnant women and newborns were calculated by pooled estimates in each trial. For two other outcomes, in each trial we constructed 2x2 contingency tables. Relative risk (RR) and the respective 95% confidence intervals (95%CI) were calculated for all effect size estimates for both individual studies and pooled estimates. Summary risk estimates were calculated using a general-variance-based fixed effect model (assessed with a homogeneity test), and the relative risks were pooled with a random effects model in cases of heterogeneity 14, 15 . We tested for homogeneity of the combined effect sizes by the χ 2 test, with p < 0.05 indicating significant heterogeneity 14, 15 . When the 2x2 tables contained 0 cells, 0.5 was added to each cell to enable our calculations to be made. Data analyses were done using the Comprehensive Meta-Analysis and Review Manager software (RevMan).
Sensitivity analysis
To evaluate the stability of the overall risk estimate, a sensitivity analysis was performed by iteratively eliminating each study and calculating the resulting RR 15 . The robustness of the results was tested by repeating the analysis using different statistical models (fixed and random effects model) 15 . We did not use funnel plots because there are numerous and confounding factors that may introduce heterogeneity in the context of observational meta-analysis 15 .
Results
Study identification and eligibility Figure 1 summarizes the study selection process. Our initial search identified 486 articles. Twenty-five met the initial eligibility criteria, and full-text articles were retrieved. We excluded 16 studies 6, 7, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 , leaving 9 included in the analysis 30, 31, 32, 33, 34, 35, 36, 37, 38 , involving a total of 2,111 pregnant women and 2,113 newborns. Inter-rater agreement for study eligibility was 79.0% (κ = 0.64), indicating good agreement 12 . Table 2 summarizes the details of participants, outcomes, and quality assessment of the studies selected for meta-analysis. Participants' ages across studies ranged from 16 to 45. All nine were prospective cohorts from a narrow population, but included sufficient details and diagnostic reference standards 30, 31, 32, 33, 34, 35, 36, 37, 38 . There were six studies with high methodological quality, satisfying greater than 86.0% of the criteria for study quality (seven or more stars for each quality criterion in the OttawaNewcastle system) 30, 31, 32, 33, 34, 36 . However, two trials were classified as level 3B, because details of the patient population including age were not reported 37 , and the sample size was small (n = 30) 38 .
Study description
486 Initial search Figure 1 Study selection process.
Studies excluded
Twenty-five studies retrieved for more detailed evaluation
Nine primary studies included in meta-analysis 30, 31, 32, 33, 34, 35, 36, 37, 38 16 studies excluded 3 review, but not systematic review 16, 17, 18 4 great of majority of the patients had history or/and PCR positive for HPV 6, 19, 20, 21 1 lost 87% subjects until delivery 22 2 not use PCR for diagnosis of HPV 23, 24 1 subjects were selected after delivery 25 2 children was not assess for HPV 7, 21 1 only children assess for HPV 26 1 duplicate Cohort study 27 2 missing data about children and mother 28 
HPV prevalence in pregnant women
In vertical transmission studies, which included mothers who were positive and negative for HPV by PCR, the percentage of positive mothers varied from 5.5% to 65.0%, with a pooled estimate of 24.3% (95%CI: 22.0-26.0) ( Table 2) . Our meta-analysis showed 139 PCR HPV-positive newborns, with a transmission rate varying from 1.5% 21 to 46.6% 25 and a combined rate of 6.5% (95%CI: 5.0-8.0).
Mother-to-child HPV transmission risk
The combined relative risk for mother-to-child HPV transmission was 7.3 (95%CI: 2.4-22.2; test for heterogeneity χ 2 = 46.3, df = 8, p < 0.001) 30, 31, 32, 33, 34, 35, 36, 37, 38 . Due to substantial heterogeneity, studies were also pooled with a random effects model, and sensitivity analysis was processed. Two studies with observed frequency equal zero in 2x2 tables 34, 37 , three studies with more than 40.0% of HPV-positive mothers 31, 36, 38 , and one that failed to satisfy the study quality criteria (≥ 87.0%) of the Ottawa-Newcastle system 35 were excluded. Thus, after sensitivity analysis, the pooled relative risk from three studies 30,32,33 was 4.8 (95%CI: 2.1-10.9). There was homogeneity between these studies (χ 2 = 3.4, df = 2, p = 0.18) (Table 3; Figure 2 ).
HPV transmission risk and mode of delivery
Seven studies compared vaginal delivery and cesarean section in HPV-positive women 30, 32, 33, 34, 35, 37, 38 . The combined relative risk for transmission according to mode of delivery was 1.8 (95%CI: 1.3-2.4). There was statistical homogeneity between studies (χ 2 = 4.20, df = 6, p = 0.6), and both the fixed and random effect models produced the same values (Table 4; Figure 3 ).
Discussion
This was the first systematic review to evaluate vertical HPV transmission. The results of this review showed that there is a risk of mother-tochild HPV transmission when the mother presents a positive HPV test. Pooled mother-tochild HPV transmission was 6.5% and was higher after vaginal delivery than cesarean section (18.0% versus 8.0%). The combined relative risk of mother-to-child HPV transmission from nine studies was 7.3 (95%CI: 2.4-22.2), but there was great heterogeneity between these studies 30, 31, 32, 33, 34, 35, 36, 37, 38 . Therefore, in this and nearly all other meta-analyses, there was extensive clinical heterogeneity, because all studies were observational. This shows that simply combining the results of studies into one overall estimate can be misleading, and that Table 2 Characteristics and assessment of quality of studies. 33 Bandyopadhyay et al. 30 Puranen et al. 32 Total (95%CI) Figure 2 Mother-to-child HPV transmission risk. Table 4 Infants born to HPV-positive mothers according mode of delivery. 33 Tenti et al. 34 Bandyopadhyay et al. 30 Xiaoping et al. 37 Tseng et al. 35 Puranen et al. 32 Xu et al. 38 Total (95%CI) 34 and Xiaoping et al. 37 found a large effect size for risk of vertical HPV transmission, because they did not have HPV-positive newborns from HPV-negative mothers (0 cells in 2x2 tables). This probably occurred because one study had a small number of HPVpositive mothers (5.2%) 34 , while the other had a limited sample (n = 73) 37 . Three other studies showed more than 40.0% of HPV-positive mothers 31, 36, 38 . Meanwhile, Xu et al. 38 had a small sample size (30 patients). Some authors have attempted to detect HPV DNA in amniotic fluid 37, 38 , while two others detected HPV DNA in newborns from swab specimens collected from the oral and/or genital mucosa 30, 31, 32, 33, 34, 35, 36 .
Smith et al. 33 detected pair concordance of HPV types in only one mother/infant pair. Furthermore, one-third of newborns tested positive who were born to mothers who had tested HPV DNA-negative during pregnancy. In some studies there was the possibility of HPV DNA contamination, because they failed to use DNA sequencing, which reduces the probability of false-negative and false-positive results 34 . In addition, there are type-discordant cases between mothers and newborns, suggesting that many of these infants did not acquire the HPV from their mothers 33 .
The seven studies that evaluated the association between mode of delivery and vertical HPV transmission showed an increased risk of HPV transmission during vaginal delivery 30, 32, 33, 34, 35, 37, 38 . We found clinical homogeneity in several characteristics. All tested the same hypothesis. They measured similar endpoints and included only HPV-positive mothers with comparable characteristics (such as age and gestational age). According to some authors, cesarean delivery could reduce transmission because it avoids ingestion of infected maternal secretions or blood during fetal passage through the birth canal 8, 35 . However, Eppel et al. 7 suggest a possible trans-placental transmission route. We thus need to consider that true infection would have occurred in uterus rather than in the birth canal 39 . We found an 8.0% HPV-positive newborn rate following cesarean section. Therefore, the cesarean delivery would not be effective for protecting newborns from HPVpositive mothers.
This meta-analysis complied with the criteria for performing a rigorous systematic review planned a priori 13, 14, 15 . This included the use of study quality assessment 10, 11 and investigation of homogeneity by fixed and random models to test the robustness of the results 13, 14, 15 . On the other hand, the potential limitations of this systematic review were the limited number of studies, as well as data which were produced from observational trials. An overall effects measure could be biased, because the confounding factors introducing heterogeneity between studies. Another limitation is that we did not search for unpublished studies.
In this systematic review, the overall results suggest that perinatal HPV transmission occurred and that newborns are at higher risk of exposure to HPV with vaginal delivery as compared to cesarean section. However, because of the heterogeneity, the mathematically pooled results should be interpreted with caution. The results of this meta-analysis showed the HPV DNA-positive rate only after birth, but an HPV DNA-positive sample does not necessarily indicate infection; it could merely indicate contamination with infected maternal cells 13 . In this systematic review, only one study followed infants for an extended period of time (36 months) 37 .
In summary, there is insufficient evidence to recommend the generalization of cesarean section for all HPV DNA-positive mothers. The critical question is not how often infants are contaminated with HPV, but how often they are infected with HPV. More studies with better methodological quality, longer follow-up, and HPV testing by DNA sequencing in this area are needed.
